Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013, Article ID 865032, 4 pages
http://dx.doi.org/10.1155/2013/865032
Case Report

PET/CT Imaging in Oncology: Exceptions That Prove the Rule

1Nuclear Medicine Unit, Department of Advanced Technology, Azienda Ospedaliera Santa Maria Nuova, IRCCS, Viale Risorgimento 80, 42123 Reggio Emilia, Italy
2Pulmonology Unit, Department of Cardiology, Thoracic and Vascular Surgery and Critical Care Medicine, Azienda Ospedaliera Santa Maria Nuova, IRCCS, Viale Risorgimento 80, 42123 Reggio Emilia, Italy

Received 22 November 2012; Accepted 31 December 2012

Academic Editors: J. Itami, M. Ryberg, and G. P. Vandoros

Copyright © 2013 M. Casali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

18F-FDG PET/CT is a diagnostic three-dimensional non-invasive device, routinely employed in neurology, cardiology, and oncology, and which contributes to patient care giving functional informations about glucose metabolism. In particular, staging, restaging, follow-up and response to treatment of tumors are the most common applications in oncologic field. Many neoplasms show increased glucose metabolism and consequent 18F-FDG uptake. Nevertheless, some relative differentiated cancers, such as clear cell carcinoma of the kidney and bronchioloalveolar adenocarcinoma, show tipically faintly/no uptake resulting in a consequent negative PET/CT scan. This case report represents an extreme case in which three relative well-differentiated cancer forms, all characterized by low glucose metabolism, affect the same patient at the same time while 18F-FDG PET/CT scan is negative.